Andrew D. Yale

Andrew D. Yale

Auto-generated profile, based on publicly available information

Andrew D. Yale

Department of Clinical Science and Services Royal Veterinary College Hatfield UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
ETElisabetta Treggiari
Elisabetta Treggiari
MPMacKenzie Arlah Pellin
MacKenzie Arlah Pellin
GRGiorgio Romanelli
Giorgio Romanelli
GMGianluca Maresca
Gianluca Maresca
IGIrina Gramer
Irina Gramer
DBDavide Berlato
Davide Berlato
Background: Tonsillar carcinomas are rarely reported in dogs. Information on outcome after treatment is sparse and prognosis is guarded to poor. Hypothesis/Objectives: Assess treatment outcome and potential prognostic factors in a population of dogs with cytological or histopathological diagnosis of tonsillar carcinoma. Animals: A total of 123 client-owned dogs with diagnosis of tonsillar carcinoma confirmed by cytology or histopathology. Methods: Retrospective, multi-institutional study. Medical records of 12 institutions were reviewed from 2012 to 2021. Results: Treatment included surgery, chemotherapy (conventional, tyrosine kinase inhibitors or metronomic chemotherapy), radiotherapy, nonsteroidal anti-inflammatory drugs (NSAIDs) or a combination of these. Surgery was performed in 68 cases, chemotherapy was administered in association with NSAIDs in 64 cases, NSAIDs were used alone in 14 cases and in association with surgery in 21 cases, whereas radiotherapy was used alone or in combination with surgery or chemotherapy in 20 cases. Overall survival time (OST) was 126 days (95% confidence interval [CI], 88-164). Significantly longer survival (P < .001) was seen in dogs without evidence of metastatic disease (median survival time, 381 days; 95% CI, 116-646). Other significant positive prognostic factors included absence of clinicals signs at presentation, surgery (tonsillectomy), use of adjuvant chemotherapy and use of NSAIDs. Conclusion and Clinical Importance: Asymptomatic dogs, those treated with surgery, those that received adjuvant chemotherapy, and those that received NSAIDs may have a better prognosis than previously expected, but overall survival remains short for dogs with tonsillar carcinoma.

25 May 2021 in Veterinary and Comparative Oncology
Verified
Journal Article
Open access
PDF file
AYAndrew D. Yale
Andrew D. Yale
SPSimon L. Priestnall
Simon L. Priestnall
RPRachel Pittaway
Rachel Pittaway
ATAngela J. Taylor
Angela J. Taylor
Canine thymic epithelial tumours (TET) are uncommon and little is known about their behaviour. Previous attempts at histologic classification have varied, and as such reliable prognostic information is unavailable. The aim of this retrospective multi‐institutional study was to evaluate cases of canine TETs, irrespective of subtype, in order to identify useful histopathologic and clinicopathologic prognostic factors. Cases were included if the tumour arose from the cranial mediastinum and a diagnosis of TET was made on the basis of histopathology. Fifty‐one dogs were included. In addition to clinicopathologic data, histology samples were reviewed for the following features: mitotic count, percentage of necrosis, presence of Hassall's corpuscles, lymphocytic infiltrate, cellular pleomorphism and vascular or capsular invasion. The median survival time for all dogs was 449 days. The 1‐ and 2‐year survival rate was 52.6% and 26.3% respectively. On multivariable analysis surgical excision of the thymic tumour was associated with significantly prolonged survival; the presence of metastasis, myasthenia gravis and moderate or marked cellular pleomorphism were associated with significantly reduced survival. Additional studies are needed to further evaluate prognostic factors to aid treatment recommendations.

1 October 2020 in Journal of Comparative Pathology
Verified
Journal Article
Closed access
AYAndrew D Yale
Andrew D Yale
BSBalazs Szladovits
Balazs Szladovits
ASAnneliese J Stell
Anneliese J Stell
SFScott D Fitzgerald
Scott D Fitzgerald
SPSimon L Priestnall
Simon L Priestnall
Alejandro Suárez-BonnetAlejandro Suárez-Bonnet
Alejandro Suárez-Bonnet

1 July 2023 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
AMAbigail McNally
Abigail McNally
MRMatteo Rossanese
Matteo Rossanese
Alejandro Suárez-BonnetAlejandro Suárez-Bonnet
Alejandro Suárez-Bonnet
ACAlexandros Chardas
Alexandros Chardas
AYAndrew D. Yale
Andrew D. Yale
Visceral hemangiosarcomas (HSA) are rare in cats and typically associated with aggressive biologic behavior and poor prognosis. A 4-year-old male neutered domestic shorthair cat was presented with a 3-month history of hematuria and stranguria; ultrasonography identified a large bladder mass. Complete excision was achieved by partial cystectomy. Histopathology and immunohistochemistry for von Willebrand factor confirmed HSA. The cat was treated using adjuvant cyclophosphamide, thalidomide, and meloxicam for 8 months. Abdominal ultrasonography repeated at 2 months and computed tomography repeated at 5 and 19 months after diagnosis showed no evidence of local recurrence or metastasis. The cat was alive at last follow-up (896 days). Although the cat described in this report experienced a more favorable prognosis compared to other visceral HSA locations, additional cases are needed to further understand the biological behavior of bladder HSAs and guide treatment decisions.

5 June 2025 in Veterinary and Comparative Oncology
Verified
Journal Article
Open access
AYAndrew D. Yale
Andrew D. Yale
ASAlvina So
Alvina So
AGAlexandra Guillén
Alexandra Guillén
IDIsabelle Desmas‐Bazelle
Isabelle Desmas‐Bazelle
FRFrancesco Rogato
Francesco Rogato
RJRosanne E. Jepson
Rosanne E. Jepson
Decreased kidney function is observed in some people receiving carboplatin, but limited literature explores this in dogs. The aim of this study was to evaluate the incidence and risk factors for decreased kidney function in dogs receiving carboplatin. A single‐institute retrospective cohort study compared the incidence of decreased kidney function between non‐azotaemic dogs receiving carboplatin and an age‐ and weight‐matched cancer‐bearing control group not receiving chemotherapy. Change in creatinine concentration and a linear mixed effects model were used to compare trends in creatinine between groups. Decreased kidney function was defined as a sustained increase in creatinine ≥ 26.5 μmol/L on ≥ 2 consecutive measurements compared to baseline; the VCOG‐CTCAE v2 grading system for increased creatinine was also applied. Risk factors were explored. Ninety‐eight dogs were included (n = 49/group). There was no difference in median change in creatinine concentration (+2.0 μmol/L; p = 0.311) or creatinine trends (p = 0.958) across the study period between groups. Incidence of decreased kidney function was low and did not significantly differ between groups (carboplatin group n = 4 [8.2%]; control group n = 2 [4.1%]; p = 0.678); no risk factors were identified. There was no difference in the frequency of VCOG grade one (p = 0.731), two (p = 0.641) or three (p = 0.429) creatinine adverse events between groups. Non‐azotaemic dogs receiving carboplatin do not have a significantly increased short‐term risk of decreased kidney function compared to those not receiving chemotherapy, although the numerical increase in incidence in dogs receiving carboplatin could be clinically relevant. Larger studies should aim to explore this further and investigate carboplatin's impact on subclinical and long‐term renal function.

23 July 2025 in Journal of Comparative Pathology
Verified
Journal Article
Open access
AGAlexandra Guillén
Alexandra Guillén
KKKara Kropp
Kara Kropp
FRFrancesco Rogato
Francesco Rogato
AYAndrew D. Yale
Andrew D. Yale
GHGabriella Hetesy
Gabriella Hetesy
AHAlexandros Hardas
Alexandros Hardas
In humans and cats, pancreatic carcinoma (PC) arising from the exocrine pancreas is considered an aggressive cancer associated with a poor prognosis due to its high metastatic rate. The aim of this retrospective multi-institutional study was to investigate tissue expression of biomarkers of tumour invasiveness, metastasis and immune escape in cats with PC. A secondary aim was to correlate the overall immunohistochemical scores (OISs) with histological characteristics, presence of metastasis and survival. Immunohistochemistry for COX-2, E-cadherin, CD44, c-KIT and PD-L1 was performed on 40 PC tissue samples. CD44 was expressed in all PCs with 27 (67 %) having a moderate to high OIS. PD-L1, E-cadherin, COX-2 and c-KIT expression was seen in 20 (50 %), 21 (52 %), 18 (45 %) and 14 (35 %) cases, respectively, with predominantly low OISs. Metastasis was present in 43 % of cats with a median survival time (MST) of 7 days (95 % CI 0-20; range, 1-1,094) and a 1-year survival rate of 13.8 %. When excluding cats that died or were euthanized at diagnosis, the MST was 19 days (95 % CI 0-99; range, 2-1,094). No statistical associations were found between COX-2, E-cadherin, PD-L1, CD44 or c-KIT OIS and histological subtype, necrosis, vascular invasion, mitotic count, presence of metastasis or survival. Positive E-cadherin expression was significantly associated with the presence of perineural invasion (P = 0.009; OR 1.50 [95 % CI 1.11-2.03]).